ProCE Banner Activity

Phase II Study: Pembrolizumab + Pomalidomide/Dexamethasone for Patients With R/R MM

Slideset Download
Conference Coverage
Early results show promising efficacy and acceptable safety profile in a heavily pretreated population.

Released: December 11, 2015

Expiration: December 09, 2016

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Amgen, Inc.

Celgene

Incyte

Merck & Co., Inc.

Millennium Takeda

Seagen